166 related articles for article (PubMed ID: 31677033)
21. Management of hearing in pediatric NF2.
Shepard TH; Tucci DL; Grant GA; Kaylie DM
Otol Neurotol; 2012 Aug; 33(6):1066-70. PubMed ID: 22710553
[TBL] [Abstract][Full Text] [Related]
22. Cochlear implantation and auditory brainstem implantation in neurofibromatosis type 2.
Peng KA; Lorenz MB; Otto SR; Brackmann DE; Wilkinson EP
Laryngoscope; 2018 Sep; 128(9):2163-2169. PubMed ID: 29573425
[TBL] [Abstract][Full Text] [Related]
23. Cochlear implants in the management of hearing loss in Neurofibromatosis Type 2.
Harris F; Tysome JR; Donnelly N; Durie-Gair J; Crundwell G; Tam YC; Knight RD; Vanat ZH; Folland N; Axon P
Cochlear Implants Int; 2017 May; 18(3):171-179. PubMed ID: 28335700
[TBL] [Abstract][Full Text] [Related]
24. Resiliency is independently associated with greater quality of life among informal caregivers to neuroscience intensive care unit patients.
Zale EL; Heinhuis TJ; Tehan T; Salgueiro D; Rosand J; Vranceanu AM
Gen Hosp Psychiatry; 2018; 52():27-33. PubMed ID: 29549820
[TBL] [Abstract][Full Text] [Related]
25. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.
Huang V; Bergner AL; Halpin C; Merker VL; Sheridan MR; Widemann BC; Blakeley JO; Plotkin SR
Otol Neurotol; 2018 Jun; 39(5):632-638. PubMed ID: 29649040
[TBL] [Abstract][Full Text] [Related]
26. Progression of hearing loss in neurofibromatosis type 2 according to genetic severity.
Emmanouil B; Houston R; May A; Ramsden JD; Hanemann CO; Halliday D; Parry A; Mackeith S
Laryngoscope; 2019 Apr; 129(4):974-980. PubMed ID: 30456886
[TBL] [Abstract][Full Text] [Related]
27. Mindfulness, coping, and optimism as mechanisms of change in the 3RP-NF intervention.
Grunberg VA; Bakhshaie J; Manglani H; Hooker J; Rochon EA; Vranceanu AM
J Clin Psychol; 2024 Feb; 80(2):456-470. PubMed ID: 38009710
[TBL] [Abstract][Full Text] [Related]
28. Stress Management and Resiliency Training (SMART) program among Department of Radiology faculty: a pilot randomized clinical trial.
Sood A; Sharma V; Schroeder DR; Gorman B
Explore (NY); 2014; 10(6):358-63. PubMed ID: 25443423
[TBL] [Abstract][Full Text] [Related]
29. Testing psychosocial mediators of a mind-body resiliency intervention for cancer survivors.
Finkelstein-Fox L; Rasmussen AW; Hall DL; Perez GK; Comander AH; Peppercorn J; Anctil R; Wang C; Park ER
Support Care Cancer; 2022 Jul; 30(7):5911-5919. PubMed ID: 35386004
[TBL] [Abstract][Full Text] [Related]
30. Virtual mind-body treatment for adolescents with neurofibromatosis: Study protocol for a single-blind randomized controlled trial.
Reichman M; Riklin E; Macklin E; Vranceanu AM
Contemp Clin Trials; 2020 Aug; 95():106078. PubMed ID: 32634485
[TBL] [Abstract][Full Text] [Related]
31. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Zhao Y; Liu P; Zhang N; Chen J; Landegger LD; Wu L; Zhao F; Zhao Y; Zhang Y; Zhang J; Fujita T; Stemmer-Rachamimov A; Ferraro GB; Liu H; Muzikansky A; Plotkin SR; Stankovic KM; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E2077-E2084. PubMed ID: 29440379
[TBL] [Abstract][Full Text] [Related]
32. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial.
Fishbein NS; Vranceanu AM; Mace RA
J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531
[TBL] [Abstract][Full Text] [Related]
33. Improving Resiliency in Healthcare Employees.
Werneburg BL; Jenkins SM; Friend JL; Berkland BE; Clark MM; Rosedahl JK; Preston HR; Daniels DC; Riley BA; Olsen KD; Sood A
Am J Health Behav; 2018 Jan; 42(1):39-50. PubMed ID: 29320337
[TBL] [Abstract][Full Text] [Related]
34. Psychosocial profiles of risk and resiliency in neurofibromatoses: a person-centered analysis of illness adaptation.
Bannon SM; Hopkins SW; Grunberg VA; Vranceanu AM
J Neurooncol; 2022 Feb; 156(3):519-527. PubMed ID: 35064449
[TBL] [Abstract][Full Text] [Related]
35. Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up.
Neff BA; Wiet RM; Lasak JM; Cohen NL; Pillsbury HC; Ramsden RT; Welling DB
Laryngoscope; 2007 Jun; 117(6):1069-72. PubMed ID: 17545869
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
Lu VM; Ravindran K; Graffeo CS; Perry A; Van Gompel JJ; Daniels DJ; Link MJ
J Neurooncol; 2019 Sep; 144(2):239-248. PubMed ID: 31254266
[TBL] [Abstract][Full Text] [Related]
37. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
38. Impact of mind-body treatment interventions on quality of life in neurofibromatosis patients: A systematic review and meta-analysis.
Wei G; Farooq J; Kumar A
Dermatol Ther; 2021 Jan; 34(1):e14613. PubMed ID: 33258517
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
